ReviewFrontiers in oncology2022
Research progress of bone metastases: From disease recognition to clinical practice.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- Clinical efficacy analysis of surgical treatment for spinal metastasis under the multidisciplinary team using the NOMS decision system combined with the revised Tokuhashi scoring system: a randomized controlled study.Journal of orthopaedic surgery and research · 2024Trial
- A workflow utilizing general-purpose large language models for efficient structuring and data mining of bone scintigraphy narratives.Scientific reports · 2026Article
- Cutting to the core: Proteases in the tumor-bone interface and metastatic progression.Biochimica et biophysica acta. Reviews on cancer · 2026Review
- Clinical Determinants of Functional Independence at Discharge in Patients With Spinal Cord Dysfunction Due to Metastatic Spinal Tumors.Archives of rehabilitation research and clinical translation · 2026Article
- Theranostics of Bone Metastases: The Role and Prospects of Bisphosphonate Radiopharmaceuticals.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Deciphering the Predictive Utility of N-telopeptide (NTx) and C-telopeptide (CTx) for Early Bony Invasion in Oral Squamous Cell Carcinoma (OSCC).Asian Pacific journal of cancer prevention : APJCP · 2026Observational
- Analysis of the heterogeneity of the immune microenvironment of bone metastases and new strategies of nanotechnology intervention.Oncology reviews · 2026Review
- Survival and Predictors in Patients With Breast Cancer Undergoing Surgery for Spinal Metastases: Insights From a Single-Center Cohort.International journal of breast cancer · 2026Article
- Biomarker-Driven Approaches to Bone Metastases: From Molecular Mechanisms to Clinical Applications.Biomedicines · 2025Review
- Invasion and metastasis in cancer: molecular insights and therapeutic targets.Signal transduction and targeted therapy · 2025Review
- Ugonin P mitigates osteolytic bone metastasis by suppressing MDK via upregulating miR-223-3p expression.International journal of biological sciences · 2025Article
- Prognostic biomarkers for overall survival in patients undergoing surgery for bone metastases: a pan-cancer study.Frontiers in medicine · 2025Article
- Microbiota-host metabolism reprogramming in colorectal cancer: from pathogenesis to precision therapies.Frontiers in oncology · 2025Review
- Can we predict neurological complications in patients with metastatic spinal tumors?Frontiers in oncology · 2025Article
- Immunotherapy in the Battle Against Bone Metastases: Mechanisms and Emerging Treatments.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Primary Bone Tumors and Breast Cancer-Induced Bone Metastases: In Vivo Animal Models and New Alternative Approaches.Biomedicines · 2024Review
- Review
- Macrophage heterogeneity in bone metastasis.Journal of bone oncology · 2024Article
- Risk factor analysis and predictive model construction for bone metastasis in newly diagnosed malignant tumor patients.American journal of translational research · 2024Article
- Long non-coding RNAs in bone metastasis: progresses and perspectives as potential diagnostic and prognostic biomarkers.Frontiers in endocrinology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone metastases, as one of the common types of metastatic tumors, have a great impact on the survival period and quality of life of patients. Bone metastases are usually characterized by bone destruction. Skeletal related events caused by bone destruction often lead to pain, pathological fractures and even paralysis. In this review, we provide a detailed explanation of bone metastases from the epidemiology, clinical features, pathogenesis, and recently developed clinical treatment viewpoints. We concluded that the incidence of bone metastases is increasing gradually, with serious clinical symptoms, complex pathogenesis and diverse clinical treatment. Tumor cells, immune cells, osteoblasts/osteoclasts and other cells as well as cytokines and enzymes all play a key role in the pathogenesis of bone metastases. We believe that the future treatment of bone metastases will be diversified and comprehensive. Some advanced technologies, such as nanomedicine, could be used for treatment, but this depends on understanding how disease occurs. With the development of treatment, the survival time and quality of life of patients will be improved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.